Mechanisms of resistance to EGFR TKIs and therapeutic perspectives in non-small cell lung cancer

doi:10.3969/j.issn.1007-3969.2013.04.012

您当前的位置：

首页 >

文章列表页 >

Mechanisms of resistance to EGFR TKIs and therapeutic perspectives in non-small cell lung cancer

更新时间：2025-12-31

- Mechanisms of resistance to EGFR TKIs and therapeutic perspectives in non-small cell lung cancer
- China Oncology Vol. 23, Issue 4, Pages: 308-314(2013)
- 作者机构：
- 作者简介：
- 基金信息：
- DOI：10.3969/j.issn.1007-3969.2013.04.012
  CLC：
- Published Online：19 November 2014，
  
  Published：2013
- 稿件说明：
移动端阅览
王珊珊综述，常建华审校. EGFR TKIs在非小细胞肺癌中的耐药机制及治疗进展[J]. 中国癌症杂志, 2013, 23(4): 308-314.

Mechanisms of resistance to EGFR TKIs and therapeutic perspectives in non-small cell lung cancer[J]. China Oncology, 2013, 23(4): 308-314.
王珊珊综述，常建华审校. EGFR TKIs在非小细胞肺癌中的耐药机制及治疗进展[J]. 中国癌症杂志, 2013, 23(4): 308-314. DOI： 10.3969/j.issn.1007-3969.2013.04.012.

Mechanisms of resistance to EGFR TKIs and therapeutic perspectives in non-small cell lung cancer[J]. China Oncology, 2013, 23(4): 308-314. DOI： 10.3969/j.issn.1007-3969.2013.04.012.

摘要

吉非替尼和厄洛替尼是表皮生长因子受体(epidermal growth factor receptor，EGFR)酪氨酸激酶抑制剂(tyrosine kinase inhibitors，TKIs)，广泛用于非小细胞肺癌的治疗。但随着应用的深入，耐药问题开始凸显。过去几年，针对继发性耐药和原发性耐药的深入研究，发现EGFR二次突变，MET基因扩增，K-ras基因突变等是EGFR TKIs耐药的主要原因。本文就EGFR-TKIs原发耐药与继发耐药的机制，以及克服此类耐药的新型药物及其临床试验数据作一综述。

Abstract

Gefitinib and erlotinib

which are epidermal growth factor receptor (EGFR) specific tyrosine kinase inhibitors (TKIs)

are widely used as molecularly targeted drugs for non-small-cell lung cancer (NSCLC). However

many patients ultimately develop resistance to these drugs. Mechanisms of acquired and primary resistance have been reported in the past few years

such as secondary mutation of the EGFR gene

amplification of the MET gene and mutations of the K-ras gene. Novel pharmaceutical agents are currently being developed to overcome resistance. This review focuses on these mechanisms of resistance to EGFR-TKIs and discusses how can be overcome.

关键词

Keywords

references

Views

5632

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Research progress of resistance to aromatase inhibitor therapy in breast cancer

Expert consensus on BRCA1/2 gene testing and clinical application in Chinese breast cancer patients (2025 edition)

Application and prospect of targeted therapy and immunotherapy in radioiodine-refractory differentiated thyroid cancer

Research progress of ALK kinase domain drug resistance mutation and its future countermeasures

Advances in the treatment ofBRAFV600-mutant non-small cell lung cancer

Related Author

李芷君

徐兵河

Hongxia WANG

Yongmei YIN

Xichun HU

Chenghe LIN

Qiuyu LIN

Yuxin WANG

Related Institution

国家癌症中心 / 国家肿瘤临床医学研究中心 / 中国医学科学院北京协和医学院肿瘤医院肿瘤内科

Committee of Breast Cancer Society, Chinese Anti-Cancer Association; Clinical Precision Medicine Professional Committee, Chinese Medical Doctor Association; Tumor Heterogeneity and Personalized Therapy Professional Committee, Chinese Anti-Cancer Association

Department of Nuclear Medicine, The First Hospital of Jilin University

Department of Oncology, the Fourth Hospital Affiliated to Hebei Medical University

天津市肿瘤医院肺部肿瘤内科

AI问答

⁰